Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PTGER2 | P43116 | 6/20 | 0.39 |
| ▸ | ICMT | O60725 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.39 |
| ▸ | DCLRE1B | Q9H816 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9890765 | 0.87 | SMN1; SMN2 (0.43) | SRCLMNARAB9ASMN1; SMN2PTGER2 | |
| SCHEMBL9890775 | 0.87 | SMN1; SMN2 (0.46) | SRCLMNASMN1; SMN2PTGER2MEN1 | |
| SCHEMBL2393439 | 0.84 | SMN1; SMN2 (0.46) | SRCLMNARAB9ASMN1; SMN2PTGER2 | |
| SCHEMBL9890679 | 0.82 | KDM4E (0.49) | SMN1; SMN2PTGER2DCLRE1B | |
| SCHEMBL9890781 | 0.81 | TP53 (0.42) | SRCLMNARAB9ASMN1; SMN2PTGER2 | |
| SCHEMBL9890786 | 0.78 | RAB9A (0.43) | LMNARAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL9890731 | 0.77 | LMNA (0.48) | SRCLMNARAB9ASMN1; SMN2TP53 | |
| SCHEMBL2396004 | 0.77 | FFAR1 (0.46) | SRCLMNARAB9ASMN1; SMN2 | |
| SCHEMBL1178097 | 0.75 | SRC (0.60) | SRCLMNAMEN1KMT2A | |
| SCHEMBL26823679 | 0.74 | CCNC (0.44) | PTGER2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| EP-2374790-A1 | BIPHENYLACETAMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | SRC 2996/4885LMNA 3980/4885RAB9A 208/4885 |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | SRC 2996/4885LMNA 3980/4885RAB9A 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.